3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
5
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Carboplatin
71
pembrolizumab
70
Pemetrexed
62
Cisplatin
46
Nivolumab
28
Paclitaxel
27
durvalumab
26
Specimen Handling
25
osimertinib
23
Docetaxel
23
Magnetic Resonance Spectroscopy
21
Gemcitabine
17
Cetuximab
15
130-nm albumin-bound paclitaxel
15
atezolizumab
14
amivantamab
14
Radiotherapy
12
Radiosurgery
12
lazertinib
11
Ipilimumab
9
Bevacizumab
9
cemiplimab
8
Taxes
8
Drug Therapy
8
alectinib
7
Ramucirumab
7
Observation
7
Radiation
6
Leucovorin
5
Immunoglobulin G
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
Ado-Trastuzumab Emtansine
×
30 days
×
Clear all
No trials found.